Clinical trials: Moderate Asthma
Asthma
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium…
- Trial name
- NCT01311661
- Testing
- Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily
- Where
- 36 sites in United States, Austria and 4 more
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Asthma, Acute Asthma
Budesonide Inhalation Suspension for Acute Asthma in Children
The purpose of this study is to determine whether the addition of budesonide inhalation suspension (BIS) to the standard therapy of albuterol, ipratropium bromide, and systemic corticosteroids (SCS) for moderate to severe asthma…
- Conditions
- Asthma, Acute Asthma, Reactive Airway Exacerbation
- Trial name
- NCT00393367
- Testing
- Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Children's Hospital of Philadelphia
Asthma
Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma
This study is being carried out to see if budesonide with HFA is effective, safe and well tolerated compared with budesonide CFC.
- Trial name
- NCT00667992
- Testing
- Budesonide HFA, Budesonide CFC
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Allergic Asthma
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics…
- Trial name
- eXplore (NCT00670930)
- Testing
- omalizumab at a dose of 0.016mg/kg/IU/mL
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over 48 weeks, compared to placebo, in children…
- Trial name
- NCT01634139
- Testing
- Tiotropium low dose QD, Tiotropium high dose QD
- Where
- 79 sites in United States, Bulgaria and 14 more
- Volunteers
- 403 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma.
- Trial name
- NCT01641081
- Testing
- Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose
- Where
- 29 sites in United States
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Asthma
Fenzian Asthma Multicenter Outcomes Study
The purpose of this study is to investigate the effects of Fenzian™ treatment on symptoms (such as shortness of breath), lung function (how well the lungs work), and albuterol/salbutamol (rescue medication) use in people with…
- Trial name
- FAMOUS (NCT00784758)
- Testing
- Fenzian Device
- Where
- 6 sites in United States, South Africa and 1 more
- Volunteers
- 81 people
- Sponsor
- University of California, Los Angeles
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603746
- Testing
- GW685698X
- Where
- 154 sites in United States, Australia and 14 more
- Volunteers
- 627 people
- Sponsor
- GlaxoSmithKline
Asthma
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
- Trial name
- GLITZ Asthma (NCT00634036)
- Testing
- pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fernando Holguin
Asthma
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Primary Objective: To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: To evaluate the effect of dupilumab at Week 24 on…
- Trial name
- VESTIGE (NCT04400318)
- Testing
- Dupilumab
- Where
- 65 sites in United States, Bulgaria and 11 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Asthma
A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
- Trial name
- NCT00419952
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Where
- 122 sites in United States
- Volunteers
- 742 people
- Sponsor
- AstraZeneca
Asthma
Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069
Distribution of neutrophils in bronchial mucosal tissue in asthma patients before and after 4 wk treatment with AZD 5069
- Trial name
- NCT01890148
- Testing
- AZD5069
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma
The aim of this trial is to select an optimum dose may be selected based on bronchodilator efficacy, safety evaluations and pharmacokinetics of tiotropium bromide.
- Trial name
- NCT01383499
- Testing
- Tiotropium bromide
- Where
- 24 sites in Germany, Hungary and 4 more
- Volunteers
- 101 people
- Sponsor
- Boehringer Ingelheim
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
GB001 in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe…
- Trial name
- NCT03683576
- Testing
- GB001
- Where
- 117 sites in United States, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Asthma
Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma
This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment, crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose levels of Albuterol Sulfate Pressurized…
- Trial name
- NCT03364608
- Testing
- AS MDI 90 μg, AS MDI 180 µg, Proventil 90 μg
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- AstraZeneca
Asthma
Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication
Determine the 24-hour FEV1-profile of tiotropium solution for inhalation after 4 weeks treatment periods of 5 mcg tiotropium administered once daily in the evening and 2.5 mcg tiotropium administered twice daily (morning and…
- Trial name
- NCT01696071
- Testing
- Tiotropium 5 mcg qd, Tiotropium 2.5 mcg bid
- Where
- 22 sites in Austria, Germany and 2 more
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Asthma
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
Primary Objective: To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).
- Trial name
- NCT03620747
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 132 sites in United States, Argentina and 8 more
- Volunteers
- 393 people
- Sponsor
- Sanofi
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline